Clinical trials: Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
- Condition Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
- Funder type Industry (pharma, biotech, devices)
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory, Refractory/Relapse Acute Myeloid Leukemia
- Trial name
- KNAN2001 (NCT04716452)
- Testing
- Ceramide NanoLiposome (Ceraxa)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Keystone Nano, Inc
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity.
- Trial name
- NCT07137637
- Testing
- HPB-092 tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Polymed Biopharmaceuticals, Inc.